Abstract 6233: APG-2575, a clinical stage BCL-2 selective inhibitor, sensitizes estrogen receptor-positive breast cancers to standard therapies in the preclinical models

2020 ◽  
Author(s):  
Douglas D. Fang ◽  
Qiuqiong Tang ◽  
Ran Tao ◽  
Guoqin Zhai ◽  
Qixin Wang ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Clinical Stage ◽  
Selective Inhibitor ◽  
Breast Cancers ◽  
Preclinical Models ◽  
Estrogen Receptor Positive

scholarly journals A Therapeutic Target for Hormone-independent Estrogen Receptor-positive Breast Cancers

2001 ◽  
Vol 7 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Debajit K. Biswas ◽  
Antonio Cruz ◽  
Nicole Pettit ◽  
George L. Mutter ◽  
Arthur B. Pardee
Keyword(s):  
Estrogen Receptor ◽  
Therapeutic Target ◽  
Breast Cancers ◽  
Estrogen Receptor Positive

scholarly journals Induction of AMPK activation by N,N’-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers

PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0209392 ◽  
Author(s):  
Jeremy Johnson ◽  
Piotr Rychahou ◽  
Vitaliy M. Sviripa ◽  
Heidi L. Weiss ◽  
Chunming Liu ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Triple Negative ◽  
Breast Cancers ◽  
Ampk Activation ◽  
Estrogen Receptor Positive

scholarly journals Long non‐coding NR2F1‐AS1 is associated with tumor recurrence in estrogen receptor‐positive breast cancers

2020 ◽  
Vol 14 (9) ◽  
pp. 2271-2287 ◽  
Author(s):  
Anna Sanchez Calle ◽  
Tomofumi Yamamoto ◽  
Yumi Kawamura ◽  
Ai Hironaka‐Mitsuhashi ◽  
Makiko Ono ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Tumor Recurrence ◽  
Breast Cancers ◽  
Estrogen Receptor Positive
Sign in / Sign up

Export Citation Format

Share Document